Human Papilloma Virus Clinical Trial
Official title:
Hashtag HPV: Engaging Parents Through Social Media to Increase HPV Vaccination
Verified date | January 2023 |
Source | University of Arkansas, Fayetteville |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Parents use social media as an important parenting tool and source for health information. Using social media data to examine public opinion has had an early impact in public health and in cancer control and prevention efforts, including about the human papillomavirus (HPV) vaccine. A next step in this area of research is to develop and share messages on social media with parents to help inform and educate them about the HPV vaccine - ultimately assisting them with their decision to vaccinate their child. This study will evaluate the efficacy of social media messages through Twitter, using a randomized controlled trial to determine what types of messages resonate with parents. The investigators will examine differences between two types of messages - narrative messages (i.e., stories) and non-narrative messages (i.e., numbers and facts).
Status | Active, not recruiting |
Enrollment | 600 |
Est. completion date | August 30, 2023 |
Est. primary completion date | August 30, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: The study population includes parents who have children ages 9-14. All participants will be 18 years of age or older, and we will specifically target parents ages 25 and older. Eligibility for enrollment in the study will be limited to the following criteria: 1. Adults 18 years of age and older; 2. Utilizes Twitter, a social media platform; 3. Has a child aged 9-14; 4. Child has not started the 2-dose HPV vaccination series; 5. Has no child who has completed any dose HPV vaccination series; 6. Has a well-care visit scheduled for their child before December, 2022. Exclusion Criteria: 1. Any adult who does not have a child 9-14 years of age; 2. Any adult who does not indicate some level of participation in Twitter; 3. Any adults who indicates a high level of anti-vaccine sentiment (assessed by vaccine hesitancy questions asked in the screener). |
Country | Name | City | State |
---|---|---|---|
United States | University of Arkansas | Fayetteville | Arkansas |
Lead Sponsor | Collaborator |
---|---|
University of Arkansas, Fayetteville | National Cancer Institute (NCI), Thomas Jefferson University, University at Albany, University of California, Los Angeles |
United States,
Massey PM, Chiang SC, Rose M, Murray RM, Rockett M, Togo E, Klassen AC, Manganello JA, Leader AE. Development of Personas to Communicate Narrative-Based Information About the HPV Vaccine on Twitter. Front Digit Health. 2021 Aug 4;3:682639. doi: 10.3389/fdgth.2021.682639. eCollection 2021. — View Citation
Massey PM, Kearney MD, Hauer MK, Selvan P, Koku E, Leader AE. Dimensions of Misinformation About the HPV Vaccine on Instagram: Content and Network Analysis of Social Media Characteristics. J Med Internet Res. 2020 Dec 3;22(12):e21451. doi: 10.2196/21451. — View Citation
Massey PM, Togo E, Chiang SC, Klassen AC, Rose M, Manganello JA, Leader AE. Identifying HPV vaccine narrative communication needs among parents on social media. Prev Med Rep. 2021 Jul 7;23:101488. doi: 10.1016/j.pmedr.2021.101488. eCollection 2021 Sep. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in caregiver self-reported HPV vaccination status of child questionnaire | dependent variable; measure collects date of vaccination and number of vaccine doses to date | Change in caregiver self-reported HPV vaccination of child at 1-month follow-up from baseline | |
Primary | Change in caregiver self-reported HPV vaccination status of child questionnaire | dependent variable; measure collects date of vaccination and number of vaccine doses to date | Change in caregiver self-reported HPV vaccination of child at 1-year follow-up from 1-month follow-up | |
Secondary | Caregiver self-reported empathy subscale adapted from Busselle & Bilandzic (2009) and Murphy, Frank, Chatterjee, Baezconde-Garbanati (2013). | mediating/moderating variable | only at 1-month post intervention | |
Secondary | Caregiver self-reported transportation subscale adapted from Murphy, Frank, Chatterjee, Baezconde-Garbanati (2013). Narrative versus Non-narrative: The Role of Identification, Transportation and Emotion in Reducing Health Disparities. | mediating/moderating variable | only at 1-month post intervention | |
Secondary | Caregiver self-reported identification subscale adapted from Murphy, Frank, Chatterjee, Baezconde-Garbanati (2013). Narrative versus Non-narrative: The Role of Identification, Transportation and Emotion in Reducing Health Disparities. | mediating/moderating variable | only at 1-month post intervention | |
Secondary | Change in caregiver self-reported intention to vaccinate their child questionnaire | dependent variable; measures readiness and likeliness to receive HPV vaccination | Change in caregiver self-reported intention to vaccinate their child at 1-month follow-up from baseline | |
Secondary | Change in caregiver self-reported intention to vaccinate their child questionnaire | dependent variable; measures readiness and likeliness to receive HPV vaccination | Change in caregiver self-reported intention to vaccinate their child at 1-year follow-up from 1-month follow-up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05329961 -
Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old, An Exploratory Immunogenicity Study
|
Early Phase 1 | |
Completed |
NCT05862844 -
Promise Women Project
|
N/A | |
Active, not recruiting |
NCT04199078 -
Clinical Trial to Explore Papilocare Gel Efficacy to Repair of the Cervico-vaginal Mucosa With HPV High Risk Lesions.
|
N/A | |
Recruiting |
NCT05566106 -
Anal Follow-up of Patients With a Gynecological History of High-grade Lesion and More Induced HPV
|
||
Not yet recruiting |
NCT06436274 -
Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV.
|
Phase 4 | |
Not yet recruiting |
NCT06229353 -
Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department
|
||
Completed |
NCT01757392 -
Candin Safety & Efficacy Study for the Treatment of Warts
|
Phase 2 | |
Active, not recruiting |
NCT04716127 -
A Proximity-incentive Strategy for Cervical Cancer Screening
|
N/A | |
Recruiting |
NCT05210348 -
Clinical Evaluation of Detection of High Risk HPV in Urine
|
||
Recruiting |
NCT05835947 -
Anal Cancer Risk In Women
|
||
Not yet recruiting |
NCT03947775 -
HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL
|
Phase 2 | |
Terminated |
NCT03404310 -
Zinc Sulfate for Human Papillomavirus (HPV)
|
N/A | |
Recruiting |
NCT03302858 -
A Safety and Efficacy Trial of Circumferential Anal Canal Radiofrequency Ablation for High-Grade Anal Intraepithelial Neoplasia Using the BARRXâ„¢ Anorectal Wand
|
Phase 2 | |
Completed |
NCT03082950 -
HPV Infections, Cancer of the Vulva and Therapeutical Success
|
||
Active, not recruiting |
NCT04950101 -
Prevalence of Anal High-risk Human Papilloma Virus Infection and Abnormal Anal Cytology in Men Who Have Sex With Men Using Pre Exposure Prophylaxis
|
N/A | |
Recruiting |
NCT05146895 -
A Cohort Study of Hyperthermia and Imiquimod for the Treatment of Flat Warts
|
N/A | |
Completed |
NCT04002154 -
Clinical Trial to Explore the Papilocare Gel Efficacy to Repair the Cervico-vaginal Mucosa With Lesions Caused by HPV
|
N/A | |
Recruiting |
NCT04232917 -
Study of 2LPAPI® on the Clearance of Genital HR-HPV Infections.
|
Phase 4 | |
Active, not recruiting |
NCT03729518 -
TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck
|
N/A | |
Recruiting |
NCT05640700 -
Vaginal Microbiome and HPV Pre-malignant and Cervical Dysplasia
|